DIA1N Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Recurring Consumables RevenueDiaSorin's business model earns a large portion of revenue from repeat purchases of reagents and assay kits used on installed instruments. This creates high revenue visibility and stickiness: once instruments are placed, ongoing utilization drives predictable, utilization-linked consumable demand over multiple years.
Strong Cash GenerationConsistent operating cash flow and high free cash flow conversion support durable financial flexibility. Strong FCF funds R&D, instrument placements, service expansion, and reduces reliance on external financing, enabling strategic reinvestment and shareholder returns over the medium term.
Improved Balance SheetMeaningfully reduced leverage lowers financial risk and increases strategic optionality. A stronger equity base and lower debt burden improve resilience through testing-demand cycles, support potential M&A or capital investments, and decrease vulnerability to interest-rate shocks over the medium term.
Bears Say
Below-Peak ProfitabilityNet margin and ROE remain below the company's earlier cycle peaks, indicating profitability has not fully recovered. Sustained lower margins constrain retained earnings and returns to shareholders, and may reflect structural price/mix pressure or higher operating costs that could persist absent operational improvements.
Historical Cash-Flow VolatilityRevenue and free cash flow have swung materially across recent years. This cyclical and volatile cash profile complicates long-term planning for capex and R&D, raises forecasting risk, and means returns and distributions could be uneven across 2–6 month horizons if testing demand or reimbursement dynamics shift.
Dependence On Testing Volumes & Installed BaseA significant portion of revenue depends on instrument placements and subsequent test utilization. Slower instrument adoption, competitive wins by rivals, or secular declines in test volumes (e.g., fewer infectious disease tests) would directly reduce consumable sales and service revenue, pressuring growth durability.
DiaSorin S.p.A. News
DIA1N FAQ
What was DiaSorin S.p.A.’s price range in the past 12 months?
Currently, no data Available
What is DiaSorin S.p.A.’s market cap?
DiaSorin S.p.A.’s market cap is $78.18B.
When is DiaSorin S.p.A.’s upcoming earnings report date?
DiaSorin S.p.A.’s upcoming earnings report date is Nov 06, 2026 which is in 54 days.
How were DiaSorin S.p.A.’s earnings last quarter?
DiaSorin S.p.A. released its earnings results on Jul 31, 2026. The company reported $20.932 earnings per share for the quarter, beating the consensus estimate of $19.317 by $1.615.
Is DiaSorin S.p.A. overvalued?
According to Wall Street analysts DiaSorin S.p.A.’s price is currently Undervalued.
Does DiaSorin S.p.A. pay dividends?
DiaSorin S.p.A. does not currently pay dividends.
What is DiaSorin S.p.A.’s EPS estimate?
DiaSorin S.p.A.’s EPS estimate is 18.25.
How many shares outstanding does DiaSorin S.p.A. have?
Currently, no data Available
What happened to DiaSorin S.p.A.’s price movement after its last earnings report?
DiaSorin S.p.A. reported an EPS of $20.932 in its last earnings report, beating expectations of $19.317. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of DiaSorin S.p.A.?
Currently, no hedge funds are holding shares in MX:DIA1N
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
DiaSorin S.p.A.
DiaSorin S.p.A. engages in research and development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, North America, and internationally. It provides various immunodiagnostic in the areas, including infectious diseases, gastrointestinal diseases, hepatitis and retroviruses, endocrinology, metabolic disorders, tumor markers, and oncology under LIAISON XL and LIAISON XS name. The company also offers Simplexa, a congenital CMV direct kit, which detects cytomegalovirus DNA in saliva swab and urine specimens. In addition, it offers LIAISON PLEX Respiratory Flex Assay and the LIAISON PLEX Yeast Blood Culture Assay. Further, the company offers xMAP technology platform, including in vitro diagnostics. The company was founded in 1968 and is headquartered in Saluggia, Italy.
DIA1N Stock 12 Month Forecast
Average Price Target
$1,330.08